Net loss was $19.3 million for the six months15 Feb 2024 07:52
The $0.8 million decrease in revenue was primarily driven by a $1.0 million decrease in KidneyIntelX billable testing volumes due to the transition to a commercial billing structure under our arrangement with Mount Sinai and a decrease of $0.2 million of pharmaceutical services revenue.
Administrative expenses for the six months ended December 31, 2023 were $18.4 million
Net loss was $19.3 million for the six months ended December 31, 2023,
Cash and cash equivalents totaled $5.6 million as of December 31, 2023.